Cover ImageSALE
市場調查報告書

老年性黃斑部病變的全球市場:2016∼2020年

Global Age-related Macular Degeneration Market 2016-2020

出版商 TechNavio (Infiniti Research Ltd.) 商品編碼 373442
出版日期 內容資訊 英文 99 Pages
訂單完成後即時交付
價格
Back to Top
老年性黃斑部病變的全球市場:2016∼2020年 Global Age-related Macular Degeneration Market 2016-2020
出版日期: 2016年09月28日 內容資訊: 英文 99 Pages
簡介

老年性黃斑部病變是眼睛的黃斑變性或崩潰,分類為乾燥型和濕潤型二種。全球老年性黃斑部病變市場,預計2016∼2020年以7.37%的年複合成長率擴大。

本報告提供全球老年性黃斑部病變市場相關調查,市場現狀及成長預測,市場規模,開發平台趨勢,各類型,各給藥途徑市場區隔,及主要供應商簡介等彙整資料。

第1章 摘要整理

第2章 本報告的範圍

第3章 市場調查方法

第4章 簡介

第5章 主要購買標準

第6章 老年性黃斑部病變概要

  • 這個疾病的理解
  • 分期
  • 病因
  • 徵兆與症狀
  • 診斷
  • 管理

第7章 產品研發線

第8章 市場情況

  • 市場概要

第9章 主要藥物的市場分析

  • Lucentis
  • Eylea
  • Avastin

第10章 老年性黃斑部病變的全球市場:各類型市場區隔

  • 濕潤型
  • 乾燥型

第11章 老年性黃斑部病變的全球市場:各給藥途徑市場區隔

  • 血管內
  • 玻璃體內

第12章 老年性黃斑部病變的全球市場:各地區市場區隔

  • 南北美洲
  • 歐洲、中東、非洲
  • 亞太地區

第13章 老年性黃斑部病變的全球市場:促進要素

  • 高齡化
  • 治療藥的償付優點的增加
  • 診斷率的上升
  • 患者和醫生的滿意度高

第14章 促進要素的影響

第15章 老年性黃斑部病變的全球市場:課題

  • 患者和眼科專家之間的供需缺口
  • 未認證藥物的使用擴大
  • 替代治療的利用可能性

第16章 促進要素與課題的影響

第17章 老年性黃斑部病變的全球市場:趨勢

第18章 供應商環境

  • 競爭模式
  • 其他值得注意的供應商

第19章 主要供應商分析

  • Bayer HealthCare
  • F. Hoffmann-La Roche
  • Novartis
  • Regeneron Pharmaceuticals

第20章 附錄

第21章 關於Technavio

目錄
Product Code: IRTNTR10443

About AMD

AMD is the degeneration or disintegration of the eye's macula. The macula is a small area of the retina that is responsible for the central vision. AMD can be classified into two types: dry and wet macular degenerations. When the tiny abnormal blood vessels begin growing toward the macula, it develops into wet AMD. Dry AMD occurs when small, yellowish deposits called drusen start accumulating beneath the macula. While some treatments are available for wet AMD; there is no treatment available at the moment for dry AMD.

Technavio's analysts forecast the global age-related macular degeneration (AMD) market to grow at a CAGR of 7.37% during the period 2016-2020.

Covered in this report

The report covers the present scenario and the growth prospects of the global age-related macular degeneration (AMD) market for 2016-2020. To calculate the market size, the report considers the revenue generated from the sales of branded, generic, and off-label drugs used for the treatment of AMD.

The market is divided into the following segments based on geography:

  • Americas
  • APAC
  • EMEA

Technavio's report, Global Age-Related Macular Degeneration (AMD) Market 2016-2020, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the market landscape and its growth prospects over the coming years. The report also includes a discussion of the key vendors operating in this market.

Key vendors

  • Bayer HealthCare
  • F. Hoffmann-La Roche
  • Novartis
  • Regeneron Pharmaceuticals

Other Prominent Vendors

  • Alcon
  • Allergan
  • Adverum Biotechnologies
  • Bausch + Lomb
  • Gilead Sciences
  • Iconic Therapeutics
  • Lpath
  • Neurotech Pharmaceuticals
  • Ohr Pharmaceutical
  • Opthea
  • Ophthotech
  • PanOptica
  • Pfizer
  • Promedior
  • QLT
  • Quark
  • Resolvyx Pharmaceuticals
  • RXi Pharmaceuticals
  • Sagent Pharmaceuticals
  • Santen Pharmaceuticals
  • Sanwa Kagaku Kenkyusho

Market driver

  • Increasing reimbursement benefits for AMD drugs
  • For a full, detailed list, view our report

Market challenge

  • Availability of alternative therapies
  • For a full, detailed list, view our report

Market trend

  • Novel treatment approaches for developing AMD drugs
  • For a full, detailed list, view our report

Key questions answered in this report

  • What will the market size be in 2020 and what will the growth rate be?
  • What are the key market trends?
  • What is driving this market?
  • What are the challenges to market growth?
  • Who are the key vendors in this market space?
  • What are the market opportunities and threats faced by the key vendors?
  • What are the strengths and weaknesses of the key vendors?

You can request one free hour of our analyst's time when you purchase this market report. Details are provided within the report.

Table of Contents

PART 01: Executive summary

  • Highlights

PART 02: Scope of the report

  • Market overview
  • Top-vendor offerings

PART 03: Market research methodology

  • Research methodology
  • Economic indicators

PART 04: Introduction

  • Key market highlights

PART 05: Key buying criteria

PART 06: AMD: Overview

  • Understanding the disease
  • Stages of AMD
  • Etiology
  • Signs and symptoms
  • Diagnosis
  • Management

PART 07: Pipeline portfolio

PART 08: Market landscape

  • Market overview

PART 09: Market analysis of major drugs

  • Lucentis
  • Eylea
  • Avastin
  • Five forces analysis

PART 10: Market segmentation by type

  • Global wet AMD market
  • Market overview
  • Global dry AMD market
  • Market overview

PART 11: Market segmentation by ROA

  • IV
  • Intravitreal

PART 12: Geographical segmentation

  • AMD market in Americas
  • AMD market in EMEA
  • AMD market in APAC

PART 13: Market drivers

  • Increase in aging population
  • Increasing reimbursement benefits for AMD drugs
  • Increase in diagnosis rate
  • High patient and physician satisfaction

PART 14: Impact of drivers

PART 15: Market challenges

  • Gap in patient demand vs. ophthalmology expert supply
  • Increasing use of off-label drugs
  • Availability of alternative therapies

PART 16: Impact of drivers and challenges

PART 17: Market trends

  • Novel treatment approaches for developing AMD drugs
  • Increased research grants, initiatives, and programs
  • Use of combination therapies

PART 18: Vendor landscape

  • Competitive scenario
  • Other prominent vendors

PART 19: Key vendor analysis

  • Bayer HealthCare
  • F. Hoffmann-La Roche
  • Novartis
  • Regeneron Pharmaceuticals

PART 20: Appendix

  • List of abbreviations

PART 21: Explore Technavio

List of Exhibits

  • Exhibit 01: Product offerings
  • Exhibit 02: Leading drugs for AMD
  • Exhibit 03: Novel opportunities for AMD market: Entry of squalamine
  • Exhibit 04: Global AMD market snapshot
  • Exhibit 05: Key buying criteria for AMD drugs
  • Exhibit 06: Key buying criteria for global AMD market 2015
  • Exhibit 07: Impact of key customer segments on global AMD market 2015
  • Exhibit 08: Stages of AMD
  • Exhibit 09: Risk factors for AMD
  • Exhibit 10: Diagnosis of AMD
  • Exhibit 11: Product portfolio of current AMD therapies
  • Exhibit 12: Share of pipeline molecules in global AMD market
  • Exhibit 13: Prevalence of AMD 2000 and 2050 (millions)
  • Exhibit 14: Global AMD market snapshot: Developed and emerging markets 2015
  • Exhibit 15: Factors influencing the global AMD market 2015
  • Exhibit 16: Global AMD market 2015-2020 ($ billions)
  • Exhibit 17: Impact of drivers and challenges of global AMD market
  • Exhibit 18: Opportunity analysis of global AMD market by type
  • Exhibit 19: Timeline of key regulatory approvals of Lucentis
  • Exhibit 20: YoY growth and revenue generated from sales of Lucentis 2013-2015 ($ billions)
  • Exhibit 21: Timeline of key regulatory approvals and filings of Eylea
  • Exhibit 22: YoY revenue and growth rate of Eylea 2012-2015 ($ billions)
  • Exhibit 23: Five forces analysis
  • Exhibit 24: Global AMD market: Segmentation by type 2015-2020
  • Exhibit 25: Global AMD market segmentation: Growth cycle analysis
  • Exhibit 26: Competitive landscape of wet AMD drugs
  • Exhibit 27: Global wet AMD market 2015-2020 ($ billions)
  • Exhibit 28: Opportunity analysis of global dry AMD market
  • Exhibit 29: Global dry AMD market 2015-2020 ($ millions)
  • Exhibit 30: Segmentation of global AMD market by ROA 2015
  • Exhibit 31: Global AMD market: Geographical outlook (2015-2020)
  • Exhibit 32: Global AMD market: Geography outlook 2015
  • Exhibit 33: Revenue/growth outlook in different countries/regions 2015
  • Exhibit 34: Global AMD market segmentation by region: Market growth lifecycle analysis 2015
  • Exhibit 35: AMD market revenue by geography 2015-2020 ($ billions)
  • Exhibit 36: Opportunity analysis of AMD market in Americas
  • Exhibit 37: AMD market in Americas 2015-2020 ($ billions)
  • Exhibit 38: Opportunity analysis of AMD market in EMEA
  • Exhibit 39: AMD market in EMEA 2015-2020 ($ billions)
  • Exhibit 40: Opportunity analysis of AMD market in APAC
  • Exhibit 41: Prevalence rates of AMD in APAC countries 2015
  • Exhibit 42: AMD market in APAC 2015-2020 ($ billions)
  • Exhibit 43: Percentage of Americans with vision loss
  • Exhibit 44: Distribution of population aged 60 years and over (millions)
  • Exhibit 45: Impact of drivers
  • Exhibit 46: Impact of drivers and challenges
  • Exhibit 47: Geographical presence of key vendors
  • Exhibit 48: Company portfolio analysis in global AMD market 2016-2020
  • Exhibit 49: Bayer HealthCare: Profile
  • Exhibit 50: Bayer HealthCare: Metrics analysis
  • Exhibit 51: Bayer HealthCare: Growth strategy matrix
  • Exhibit 52: Bayer HealthCare: Opportunity assessment
  • Exhibit 53: F. Hoffmann-La Roche: Profile
  • Exhibit 54: F. Hoffmann-La Roche: Metrics analysis
  • Exhibit 55: F. Hoffmann-La Roche: Growth strategy matrix
  • Exhibit 56: F. Hoffmann-La Roche: Opportunity assessment
  • Exhibit 57: Novartis: Specialty ophthalmic segmentation by revenue 2015
  • Exhibit 58: Novartis: Profile
  • Exhibit 59: Novartis: Metrics analysis
  • Exhibit 60: Novartis: Growth strategy matrix
  • Exhibit 61: Novartis: Opportunity assessment
  • Exhibit 62: Regeneron Pharmaceuticals: Profile
  • Exhibit 63: Regeneron Pharmaceuticals: Metrics analysis
  • Exhibit 64: Regeneron Pharmaceuticals: Growth strategy matrix
  • Exhibit 65: Regeneron Pharmaceuticals: Growth opportunity assessment
Back to Top